SCHEMBL22687815

SCHEMBL22687815

CCOC(=O)C[C@H](C)NC1(CC(=O)OCC)CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.39
▸ MGAM O43451 1/20 0.39
▸ SI P14410 1/20 0.39
▸ MGAM2 Q2M2H8 1/20 0.39
▸ CYP2D6 P10635 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.33
▸ TRPA1 O75762 1/20 0.33
▸ ALOX15 P16050 4/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ TSHR P16473 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ UGT2B7 P16662 2/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ ADORA1 P30542 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22658502 0.91 GAA (0.37) GAAMGAMSIMGAM2CYP2D6
SCHEMBL22658488 0.91 GAA (0.37) GAAMGAMSIMGAM2CYP2D6
SCHEMBL15461446 0.85 GAA (0.43) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL15461455 0.80 GAA (0.42) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL30140982 0.75 GAA (0.48) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL16276873 0.71 GAA (0.48) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL7835239 0.71 GAA (0.52) GAAMGAMSIMGAM2CYP2D6
SCHEMBL15461464 0.71 GAA (0.39) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL17628821 0.70 GAA (0.42) GAAMGAMSIMGAM2L3MBTL1
SCHEMBL22338084 0.69 GAA (0.45) GAAMGAMSIMGAM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 — — US disclosed
EP-3969446-B1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2023-09-27 — — EP disclosed
EP-3969446-B1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2023-09-27 — — EP disclosed
EP-4219466-A1 COMPUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-08-02 — — EP disclosed
EP-4219466-A1 COMPUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-08-02 — — EP disclosed
US-20220204478-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2022-06-30 — — US disclosed
EP-3969446-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2022-03-23 — — EP disclosed
WO-2020231977-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2020-11-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204478-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH GAA 11/4885MGAM 2552/4885SI 2850/4885
US-12577226-B2 Compounds for treating Huntington's disease HTT, HYPK, GRIN2C GAA 334/4885MGAM 4479/4885SI 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback